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Effects of calcitriol administration on calcium metabolism in healthy
men. To evaluate the relationship between daily and fasting urinary
calcium excretion and serum I ,25-(OH)2-D concentrations, we studied
six healthy men during control and during chronic oral calcitriol
administration (0.6, 1.2, or 1.8 nmoles every 6 hours for 6 to 12 days)
while they ate normal and low calcium diets (calcium content, 19.2 or
4.2 mmoles/day). Daily urinary calcium excretion was directly related
to serum l,25-(OH)2-D concentrations but increased more (P < 0.025)
while subjects ate the normal calcium diet (slope, 0.081 mmole/day/
pmole/liter; r = 0.94) than when eating the low calcium diet (slope,
0.043 mmole/day!pmole/liter; r = 0.83). During calcitriol and ingestion
of the low calcium diet, daily urinary calcium excretion averaged 7.32
2.6 mmoles/day, exceeding the dietary calcium intake (P < 0.02).
Moreover, during calcitriol, when serum I ,25-(OH)2-D exceeded 140
pmoles/liter, fasting urinary calcium/creatinine exceeded 0.34 mmole!
mmole (the upper limit of normal) on either diet. When serum I ,25-
(OH)2-D concentrations are elevated, a high fasting urinary calcium!
creatinine or high daily urinary calcium excretion, even on a low
calcium diet, is insufficient criteria for the documentation of a renal
calcium leak.
Effets de l'administration de calcitriol sur le métabolisme du calcium
chez hommes en bonne sante. Afin d'évaluer Ia relation entre l'excrétion
urinaire quotidienne de calcium, l'excrétion de calcium a jeun et Ia
concentration sérique de I ,25-(OH)2-D, nous avons étudié six hommes
bien portants au cours de périodes contrôles et au cours de l'administra-
tion de calcitriol chronique par voie orale (0,6, 1,2, ou 1,8 nmoles
chaque 6 heures pendant 6 a 12 jours) au cours de l'ingestion d'une
alimentation normale ou pauvre en calcium (19,2 ou 4,2 mmoles de
calcium par jour). L'excrétion urinaire de calcium quotidienne est
directement liée a Ia concentration sérique de l,25-(OH)2-D mais elle
augmente plus (P < 0,025) quand les sujets ont une alimentation
normale en calcium (pente 0,081 mmoles/jour par pmole par litre; r =
0,94) que lorsqu'ils ont une alimentation pauvre en calcium (pente 0,043
mmoles/jour par pmole par litre; r = 0,83). Au cours de l'ingestion de
calcitriol et d'une alimentation pauvre en calcium, l'excrétion urinaire
quotidienne de calcium est en moyenne de 7,32 2,6 mmoles/jour,
supérieure a l'ingestion de calcium (P < 0,02). De plus, au cours de
l'ingestion de calcitriol, quand Ia concentration sérique de I ,25-(OH)2-D
dépasse 140 pmole par litre, le rapport calcium/créatinine dans l'urine a
jeun est supérieur a 0,34 (limite supérieure de Ia normale) quelle que soit
l'alimentation. Quand les concentrations sériques de I ,25-(OH)2-D sont
Clevées, un rapport calcium/créatinine élevé dans l'urine ou une excré-
tion urinaire de 24 heures élevée sont insuffisants, méme au cours d'une
alimentation pauvre en calcium, pour établir l'existence d'une fuite
rénale de calcium.
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Hypercalciuria is a risk factor in the pathogenesis of calcium-
containing kidney stones. Increased intestinal calcium absorp-
tion [1—10], stimulated by raised serum concentrations of the
renal hormone 1,25-(OH)2-vitamin D [11—131, is well docu-
mented in calcium stoneformers and certainly accounts for
some, if not all, of the increased urinary calcium. The stimulus
to increased 1 ,25-(OH)2-D levels in stoneformers cannot always
be identified. A PTH-mediated increase in renal synthesis,
secondary to a renal calcium leak, is present in some patients
[13, 14]. Pak has used the magnitude of urinary calcium
excretion on a low calcium diet or after overnight fasting to
differentiate those patients with a renal calcium leak from those
with another stimulus to increased 1,25-(OH)2-D synthesis [101.
The studies reported here were designed to determine the
effects of experimental elevation of serum concentrations of
1,25-(OH)2-D on daily and fasting urinary calcium excretion.
Elevation of serum 1 ,25-(OH)2-D concentrations increased dai-
ly, as did the fasting urinary calcium, indicating that fasting
hypercalciuria alone is insufficient to document a renal calcium
leak.
Methods
Six healthy men with no personal or family history of kidney
stones were studied in the Medical College of Wisconsin
Clinical Research Center with their consent and the approval of
the Medical College of Wisconsin Human Research Review
Committee. The men were studied while they ate a normal
calcium diet (19.3 [SDI 0.3 mmoles/day) and a low calcium
diet (4.2 0.4 mmoles/day). The normal diet also provided
2,720 250 calories/day, with an electrolyte content of 43 I
phosphorus, 9.7 0.4 magnesium, 77 2 potassium, 130 9
sodium, 69 10 chloride, and 1.0 0.1 oxalate, all in mmoles/
day. The low calcium diet composition was similar except for a
higher oxalate content of 3.7 0.1 mmoles/day. Each subject
ate each of the diets for 3 or 4 days during a control (no
treatment) period and a calcitriol (Rocaltrol®, Roche) period.
Calcitriol was given to two subjects at a dose of 2.4 nmoles/day,
to two others at a dose of 4.8 nmoles/day, and to a further two at
7.2 nmoles/day (1,2, and 3 pg/day, respectively). Calcitriol was
started 4 days prior to the inpatient study periods and was taken
in divided doses at 0600, 1200, 1800, and 2400 hours. The
control and calcitriol phases were separated by at least I month.
Blood samples were obtained at 0600, 1000, 1600, and 2000
hours of day 3 and at 0600 and 1000 hours of day 4 of each diet.
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Table 1. Mean serum I ,25-(OH)2-D concentrations during control and during calcitriol administration'
Control
Serum 1 ,25-(OH)2-D, pmoles/Iiter
Calcitriol
Calcitriol dose
nmoles/day
Serum 1 ,25-(OH)2-D, pmoleslliter
Subject Normal Ca diet Low Ca diet Normal Ca diet Low Ca diet
69 15 70 9 2.4 76 5 110 13
(5) (4) (5) (4)
2 109 7 112 10 2.4 141 18 158 14
(4) (4) (5) (4)
3 62 6 118 23 4.8 183 42 172 70
(4) (5) (4) (5)
4 95 9 126 11 4.8 186 21 212 35
(4) (5) (4) (5)
5 106 17 132 30 7.2 184 36 235 49
(5) (4) (7) (6)
6 93 11 110 21 7.2 208 49 196 35
(5) (4) (7) (5)
Group
mean 89 19 Ill 21 163 48 180 44
Comparison of normal and low Ca diets <0.05 NS
Comparison of control and calcitriol administration <0.025 <0.005
a Means SD. Numbers in parentheses represent Ihe number of separate serum samples for each subject.
On days 3 and 4, 2-hr fasting morning urine samples were
collected from 0600 to 0800 hours, 10 to 12 hours after the last
meal. Urine was then collected after breakfast on days 3 and 4
from 0800 to 1200 hours. The remainder of day 3's urine was
collected (1200 to 0600 hours). A 25-mmole calcium load was
given with breakfast on morning 4 of each diet (calcium
gluconate, Neocalglucon®, Dorsey).
Serum and urinary calcium, phosphate, magnesium, and
creatinine, and diet calcium for the low calcium diet were
measured using previously described techniques [IS]. Serum
PTH was measured with antibody, kindly provided by Dr.
Eduardo Slatopolsky, Washington University School of Medi-
cine, St. Louis. Dr. David Cohn, University of Kansas School
of Medicine, kindly provided highly purified bovine PTH (b
PTH) from which '251-bPTH trace was prepared. Results are
reported in dilutions of a standard serum obtained from a
patient with a functioning parathyroid carcinoma. Bound and
free trace were separated using dextran-coated charcoal [16].
Serum, l,25-(OH)2-D was measured as previously described
[17]. For the 1 ,25-(OH)2-D assay, the individual coefficients of
variation for all samples for each subject averaged 16% com-
pared with 17.5% for a plasma pool in 22 separate assays during
the period over which these studies were performed. Serum
PTH and I ,25-(OH)2-D for each subject were measured in the
same assay. Hydroxyproline in fasting morning urine samples
was measured by the method of Woessner [18]. Urinary oxalate
was measured by the method of Hodgkinson and Williams [19].
Recovery of oxalate added to urine averaged 92 14% (25
assays). Daily urinary oxalate excretion in 42 other healthy
adults averaged 0.36 0.10 mmoles/day (32 9 mg/day).
Glomerular filtration rates were estimated from endogenous
creatinine clearances. Fasting TmPO4/GFR was estimated from
the Bijvoet nomogram [20]. Because the directional changes
observed were independent of calcitriol dose, we have pooled
data for all six subjects to simplify presentation of results.
Group data are presented as means SD. Changes from control
were evaluated by Student's paired t test. Linear regressions
were calculated by least squares [21].
Results
Effects of the low calcium diet on serum and urine composi-
tion. The first two columns of Tables 1 and 2 present fasting and
mean serum compositions and daily and fasting urine composi-
tions during control periods when the subjects were eating the
normal and low calcium diets. In comparison to observations
made when the subjects were eating the normal diets, ingestion
ofthe low calcium diet decreased daily urine calcium excretion
by —2.34 1.25 mmoles/day (P < 0.01) and raised serum 1,25-
(OH)2-D concentrations 22 19 pmoles/liter (P < 0.05). No
change in fasting or mean serum calcium or PTH concentrations
was detected. Daily urinary oxalate excretion was higher on the
low calcium diet (P <0.05).
Effects of chronic oral calcitriol administration on plasma
concentrations of the hormone. Table 1 presents the individual
calcitriol doses and the individual mean serum 1 ,25-(OH)2-D
concentrations for the subjects during calcitriol administration.
Chronic calcitriol raised serum concentrations of the hormone
in each subject on both diets. For all six subjects, serum 1,25-
(OH)2-D levels averaged 163 48 pmoles/liter during the
normal calcium diet and were slightly but not significantly
higher at 180 44 pmoles/liter during the low calcium diet.
Figure 1 shows serum 1,25-(OH)2-D levels in each subject
over 24 hours of day 3 of each diet during both control and
calcitriol administration. We could not detect a diurnal varia-
tion of serum 1 ,25-(OH)2-D concentrations during control on
either diet. When the subjects were taking calcitriol, the blood
sampling times on day 3 of each diet corresponded to 2, 4, and 6
hours after the previous calcitriol dose. Serum concentrations
of 1,25-(OH)2-D did not vary significantly at these respective
sampling times: 124, 126, and 115 pmoles/liter for the subjects
taking 0.6 nmoles every 6 hours; 172, 198, and 172 pmoles/liter
for the subjects taking 1.2 nmoles every 6 hours; and 170, 221,
and 208 pmoles/liter for the subjects taking 1.8 nmoles every 6
hours. Thus, the men achieved stable, elevated serum 1,25-
(OH)2-D concentrations after at least 6days of calcitriol admin-
istration.
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Table 2. Serum and urine composition during control and during chronic calcitriol while eating normal and low calcium dietsa
Comparisons (P values)
Calcitriol vs.
Control: control Calcitriol:
Control Calcitriol Low vs.
normal
diets
Normal Low
Ca Ca
Low vs.
normal
dietsNormal Ca diet Low Ca diet Normal Ca diet Low Ca diet
Fasting serumb
Ca, mM 2.39 0.10' 2.40 0.06 2.44 0.05 2.48 0.07 NS NS NS NS
PTH, j.lEqIm! 6.8 3.0 6.7 2.7 5.4 2.1 4.8 2.4 NS NS <0.05 NS
P04, mM 1.40 0.17 1.33 0.09 1.44 0.16 1.37 0.12 NS NS NS NS
Mg, mM 0.91 0.03 0.92 0.03 0.86 0.02 0.88 0.03 NS <0.01 <0.02 NS
Creatinine, p.M 108 15 112 16 113 16 114 15 NS NS NS NS
Mean seruma
Ca, mM 2.44 0.07 2.40 0.10 2.54 0.05 2.47 0.06 NS <0.05 NS NS
PTH, p.lEqIml 6.9 3.! 6.9 2.6 4.8 2.2 4.6 2.4 NS <0.05 <0.01 NS
P04, mM 1.34 0.10 1.25 0.07 1.38 0.10 1.28 0.08 NS NS NS <0.05
Mg, mM 0.92 0.04 0.93 0.03 0.86 0.02 0.88 0.04 NS <0.01 <0.02 NS
Daily urine4
Creatinine, mmo!eslday 18.6 1.2 18.8 0.7 18.7 0.7 19.6 0.6 NS NS NS <0.02
Ca, mmoleslday 5.96 2.00 3.63 1.37 13.0 3.08 7.32 2.06 <0.01 <0.005 <0.01 <0.001
P04, mmoles/day 40.0 4.0 35.9 3.8 37.5 3.7 42.8 4.0 NS NS <0.05 NS
Mg, mmo!eslday 5.55 0.65 4.53 0.98 5.90 1.00 4.87 0.64 <0.02 NS NS <0.05
Oxalate, mmoles/day 0.31 0.06 0.36 0.05 0.33 0.04 0.37 0.04 <0.05 NS NS NS
Fasting urinea
Calcreatinine,
mmole/mmole 0.161 0.057 0.202 0.096 0.369 0.116 0.358 0.062 NS <0.02 <0.05 NS
P/creatinine, mmole/mmo!e 1.46 0.29 1.25 0.27 1.61 0.22 1.62 0.33 NS NS NS NS
TmPO4IGFR, ,nM 1.36 0.12 1.35 0.17 1.33 0.11 1.25 0.06 NS NS NS NS
Mg/creatinine,
mmo!elmmole 0.23 0.08 0.26 0.05 0.22 0.08 0.27 0.07 NS NS NS NS
Hydroxyproline/creatinine,
i.molelmmole 3.5 1.7 3.2 1.2 4.4 2.2 4.3 1.8 NS NS NS NS
Oxalate/creatinine,
p.mo!elmmo!e 10 2 11 3 13 3 15 3 NS NS <0.05 NS
a Mean SD.
b Individual subject averages of blood samples obtained at 0600 hours on days 3 and 4 of each diet.
Individual subject averages of blood samples obtained at 0600, 1000, 1600, and 2000 hours on day 3 and at 0600 hours on day 4 of each diet.
Daily urine composition on day 3 of each diet.
Average composition of urine samples taken when patients fasted on days 3 and 4 of each diet.
Effects of chronic calcitriol administration on serum and
urine composition. Table 2 shows fasting and mean serum
calcium, PTH, phosphate, and magnesium and fasting serum
creatinine and daily urinary excretion of creatinine, calcium,
phosphate, magnesium, and oxalate. Fasting urine composition
is also shown. Columns 3 and 4 show the results of chronic
calcitriol administration during normal and low calcium diets.
Chronic calcitriol administration resulted in a significant rise in
mean serum calcium concentration during the normal calcium
diet (+0.10 0.08 mM; P < 0.05) and a slight but insignificant
rise during the low calcium diet (+0.07 0.08 mM; NS). This
was accompanied by a fall in mean PTH levels during calcitriol
for both diets (normal calcium diet: —1.5 0.6 p.lEq/ml: P <
0.025, and low calcium diet: —2.7 1.2 p.lEq/ml; P < 0.005).
Similar directional changes were seen in the fasting serum
calcium and PTH levels but these were not significant. With
both diets urinary calcium excretion increased during calcitriol
administration (Table 2): Urinary calcium excretion averaged
7.32 2.06 mmoles/day during the low calcium diet. This
quantity of calcium was 178 52% of the calcium intake (P <
0.02 compared to 100%). Fasting urine calcium/creatinine in-
creased during calcitriol administration (normal calcium diet:
+0.207 0.131 mmole/mmole, P < 0.025; and low calcium diet:
+0.156 0.070 mmole/mmole, P < 0.005).
Calcitriol administration was not associated with a significant
change in mean or fasting serum phosphate concentration.
Daily urinary phosphate excretion was not changed during the
normal calcium diet although it rose slightly during the low
calcium diet (+6.9 5.6 mmoles/day; P < 0.05). There were no
significant changes in fasting urinary phosphate/creatinine or in
TmPO4IGFR during calcitriol administration (Table 2). Calci-
triol administration resulted in a significant fall in fasting and
mean serum magnesium concentrations. Daily urinary magne-
sium excretion rose slightly but not significantly during calci-
triol. Fasting urinary magnesium!creatinine was unchanged.
Chronic calcitriol administration did not change the fasting
serum creatinine and daily urinary creatinine excretion, the
daily urinary oxalate excretion, or the fasting urinary hydroxy-
proline/creatinine.
Correlations between changes in serum and urine composi-
tion and changes in serum l,25-(OH)2-D concentrations. As
shown in Figure 2, endogenous creatinine clearance did not
change during calcitriol administration as serum 1 ,25-(OH)2-D
concentrations increased. The individual changes in serum
calcium were significantly correlated to changes in serum 1,25-
(OH)2-D concentrations during the normal calcium diet (r =
0.97; P < 0.01) but not during the low calcium diet (r = 0.70; P
> 0.1). For both diets, the changes in urinary calcium excretion
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Fig. 1. Individual serum I,25-(OH)2-D
concentrations at 0600, 1600, and 2000
hours on day3 and at 0600 hour of day4of
each diet during control conditions and
during chronic oral calcitriol administra-
tion. The normal calcium diet is shown
with solidsymbols and solid lines; and the
low calcium diet, with open symbols and
broken lines. The arrows indicate the ad-
ministration of calcitriol at 0600, 1200,
1800, and 2400 hours. The circles (• and
0), squares (I and 0), and triangles (A
and L) indicate the subjects given 0.25,
0.5, and 0.75 g (0.6, 1.2, and 1.8 nmoles)
of calcitriol every 6 hours, respectively.
were significantly correlated to the changes in serum 1,25-
(OH)2-D concentrations (normal calcium diet: r = 0.94, P <
0.01; and low calcium diet: r = 0.84, P < 0.05). The slopes of
these regression relationships are not different, but the inter-
cepts of the two regression equations are significantly different
(P < 0.005).
No significant correlations were observed between changes
in mean serum phosphate, daily urinary phosphate excretion,
mean serum magnesium, and daily urinary magnesium excre-
tion and the changes in serum 1 ,25-(OH)2-D concentrations (not
shown).
Correlations of serum and urine composition to mean serum
1,25-(OH)2-D concentrations. As shown in Figure 3, daily
urinary calcium excretion was significantly and positively cor-
related to the mean serum 1,25-(OH)2-D concentration during
the normal calcium diet (r = 0.94; P < 0.001) and the low
calcium diet (r = 0.83; P < 0.01). The slope of urine calcium
excretion on serum 1,25-(OH)2-D was significantly greater
during the normal diet (0.081 and 0.043 mmole/day/pmole/liter,
normal vs. low calcium, respectively, P < 0.025), but the
intercepts of the regression lines were not different.
The left panel of Figure 4 shows that fasting urinary calcium!
creatinine was significantly correlated to the mean serum 1,25-
(OH)2-D concentrations during the normal calcium diet (r =
0.78; P < 0.01) and the low calcium diet (r = 0.66; P < 0.05).
These regressions are not different. When serum 1 ,25-(OH)2-D
concentrations exceeded 140 pmoles/liter, a value of 2 SD above
the mean for 97 healthy adults [22], fasting urinary calcium!
creatinine averaged 0.39 0.06 mmole/mmole or 0.138 0.021
mg/mg, a value above (P < 0.05) the accepted upper limits of
normal of 0.34 mmole/mmole or 0.12 mg/mg [23]. The middle
panel of Figure 4 shows that urinary calcium/creatinine after
breakfast was also significantly correlated to mean serum 1,25-
(OH)2-D concentrations for each of the two diets. The low
calcium breakfast provided only 1 mmole of calcium and did not
1 2 00
6 0 660 0 000 0 00
Time of day, hr
serum 1 ,25-(OH)2-D concentration from that observed during
fasting. By contrast, the normal calcium diet breakfast provided
7.5 mmoles of calcium, which significantly increased the slope
of the regression of urine calcium!creatinine on 1 ,25-(OH)2-D
concentrations (0.00483 vs. 0.00183 mmole/mmole/pmole/liter;
P < 0.005). The right panel of Figure 4 shows that urine
calcium/creatinine increased comparably as a function of serum
1 ,25-(OH)2-D concentrations after breakfast plus a 25-mmole
calcium load along with the normal calcium diet (r= 0.87; P <
0.01) or low calcium diet (r = 0.67; P < 0.05). The slopes of
these regressions are not significantly different (0.00650 vs.
000384 mmole/mmole/pmole/liter; P > 0.1). Finally, the re-
sponses to breakfast or breakfast plus the calcium load on
serum phosphate, urinary phosphate, TmPO4/GFR, serum mag-
nesium, and urinary magnesium were not different during
calcitriol in comparison to control (not shown).
Daily urinary oxalate excretion was not correlated to the
mean serum I ,25-(OH)2-D concentration for subjects eating
either normal or low calcium diets. On the other hand, fasting
urinary oxalate excretion/creatinine was significantly correlated
to serum 1,25-(OH)2-D concentrations during the low calcium
diet: fasting urine oxalate/creatinine, in mmole/mmole, = 3.8 +
0.065 x serum 1,25-(OH)2-D, in pmoles/liter; r = 0.64; P <
0.05, and approached a significant correlation during the normal
calcium diet (r = 0.55; 0.1 > P > 0.05). Fasting urinary
hydroxyproline/creatinine was not correlated to serum 1,25-
(OH)2-D concentrations.
Discussion
The major biologic effect of 1 ,25-(OH)2-D is to stimulate
intestinal calcium absorption [13, 24, 25]. When serum 1,25-
(OH)2-D concentrations were raised by calcitriol administration
to subjects eating a normal calcium diet, urinary calcium
excretion increased. This increase was proportional to the
Control
Normal Ca diet Low Ca diet
1, 25-(OH)-D3
Normal Ca diet Low Ca diet
A
12600000
6 6 4 6 66 6 6 4 4
) 12
6 0 66 6 0 60 0 00 0 0 00 0 00 0 0 0
alter the relationship between urinary calcium!creatinine and
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+0.20
E
E-5 +0.10'
6 +20 +40 +60 +80 +100 +120
Serum 1 ,25-(OH)2-D, pmoles/liter
Fig. 2. Individual changes from control of mean serum calcium
concentration, endogenous creatinine clearance, and daily urinary
calcium excretion as functions of the individual changes from control of
mean serum 1,25-(OH)2-D concentrations. Symbols and lines are
defined in Fig. 1.
prevailing serum l,25-(OH)2-D levels (Fig. 3) and reached
hypercalciuric rates of greater than 7.5 mmoles/day. Urinary
calcium/creatinine increased progressively in proportion to
serum I ,25-(OH)2-D concentrations when the subjects ingested
increasing amounts of calcium with breakfast (Fig. 4). These
data confirm observations in patients with nephrolithiasis and
hypercalciuria [26] and with hyperparathyroidism [27], which
indicate that urinary calcium excretion is critically determined
by serum 1,25-(OH)2-D concentrations. Together, these obser-
vations provide further evidence that the most important effect
of 1,25-(OH)2-D is to stimulate intestinal calcium absorption.
When the subjects were eating the normal calcium diet, fasting
urinary calcium/creatinine also increased as serum 1 ,25-(OH)7-
D concentrations increased. This suggests that fasting urinary
calcium reflects ongoing intestinal calcium absorption 10 to 12
hours following the last calcium-containing meal. This can be
explained either by delayed intestinal transit of calcium beyond
the jejunum, the principal site for calcium absorption, or by
l,25-(OH)2-D stimulated calcium absorption in the colon, as
observed in animals [28].
I I I
0 50 100 150 200 250
Serum 1,25-(OH)2-D,pmo/es//iter
Fig. 3. Daily urinary calcium excretion for control (• and 'O) and for
subjects given chronic oral calcitriol (* and ), during the normal
calcium diet (solid symbols) and during the low calcium diet (open
symbols), as afunction f individual mean serum 1,25-(OH)2-D concen-
trations.
Studies in animals suggest that l,25-(OH)2-D is also capable
of stimulating bone resorption [29, 30]. In an effort to detect
such an effect in humans, we evaluated urine composition when
serum 1 ,25-(OH)2-D concentrations were elevated and the
subjects were eating a low calcium diet, to limit expression of
the effect of l,25-(OH)2-D to stimulate intestinal calcium ab-
sorption. Daily urinary calcium excretion and fasting urinary
calcium/creatinine did increase in proportion to serum 1,25-
(OH)2-D levels for the subjects taking calcitriol and eating a diet
providing a calcium content of only 4.2 mmoles/day. But these
data do not conclusively support an effect of 1,25-(OH)2-D to
stimulate bone resorption. Such a conclusion is limited by at
least three factors. First, the subjects ate the low calcium diet
for only 3 or 4 days. A longer period of dietary adaptation may
be required to exclude ongoing intestinal absorption of previ-
ously ingested calcium. This could account for the observation
that calcium excretion exceeded dietary calcium intake on day 3
of the low calcium diet during calcitriol administration. Second,
balance studies were not performed to document that negative
calcium balances (urinary calcium excretion exceeding net
intestinal calcium absorption) resulted when subjects with
elevated serum l,25-(OH),-D concentrations ate the low calci-
um diet. Third, fasting urinary hydroxyproline/creatinine did
not increase as serum 1 ,25-(OH)2-D levels were experimentally
raised, Stimulation of bone resorption by high serum I ,25-
(OH)2-D concentrations should have increased urinary hy-
droxyproline as well as urinary calcium because bone matrix
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Fig. 4. Individual urinary calcium/creatinine for control and ca/curio/-treated subjects, during fasting, after breakfast, and after breakfast plus the
25-mmole Ca load, as a function of the individual mean serum l,25-(OH)2-I) concentrations. Symbols are defined in Fig. 3.
and mineral are resorbed together [31]. Thus, the source of the
additional urinary calcium is more likely the diet. Long-term
balance studies before and during chronic calcitriol administra-
tion will be required to clarify the effect of high serum 1,25-
(OH)2-D levels on bone resorption in humans.
The relationships between urinary calcium excretion and
serum 1 ,25-(OH)2-D concentrations have implications for the
detection of a renal calcium leak in patients with nephrolithia-
sis. Fasting urinary calcium/creatinine will be elevated in pa-
tients with high serum 1 ,25-(OH)2-D concentrations who have
been eating a normal calcium diet and cannot be taken as
evidence of a renal calcium leak. Similarly, fasting urinary
calcium/creatinine may be elevated in subjects with high 1,25-
(OH)2-D concentrations even after 3 or 4 days of dietary
calcium deprivation. For several reasons this observation also
cannot be taken as evidence of a renal calcium leak. First,
calcium from a previously higher diet calcium level may not
have cleared the intestine and would be available for absorp-
tion. Second, maximally efficient intestinal absorption of even
small quantities of dietary calcium may produce fasting urine
calcium/creatinine above normal. For example, fasting urine
calcium/creatinine could be 0.37 mmole/nimole or 0.13 mg/mg,
above the upper limit of normal, for a 70-kg man with an
elevated serum l,25-(OH)2-D level (diet calcium, 10 mmoles/
day; net intestinal calcium absorption, 55%;creatinine produc-
tion, 24 mg/kg/day; and uniform calcium and creatinine excre-
tion throughout the day). Third, the possibility remains that
raised serum 1,25-(OH),-D levels stimulate net bone resorption,
resulting in high fasting urine calcium/creatinine, as well as
increased daily urine calcium excretion. These considerations
indicate that neither elevated fasting urine calcium/creatinine
nor daily urine calcium provide evidence for a renal calcium
leak during short-term dietary calcium deprivation when serum
l,25-(OH)2-D levels are high. Documentation of such a leak
would require additional evidence of hypocalcemia and second-
ary hyperparathyroidism.
Another biologic action of l,25-(OH)2-D3 is to stimulate
intestinal phosphate absorption [32], an effect particularly evi-
dent in subjects who are deficient in vitamin D. We have
previously been unable to detect a significant relationship
between net intestinal phosphate absorption and prevailing
serum 1,25-(OH)2-D concentrations [12]. In the present studies
when serum l,25-(OH)2-D levels were elevated and the men
were eating the normal calcium diet, neither serum phosphate
concentrations nor urinary phosphate excretion rates changed.
This implies that intestinal phosphate absorption was not signif-
icantly enhanced. The fall in serum PTH levels resulting from
the rise in serum calcium concentrations during calcitriol ad-
ministration would have been expected to elevate fasting
TmPO4/GFR, but this was not seen (Table 2). Studies in animals
provide evidence that 1 ,25-(OH)2-D3 can enhance urinary phos-
phate excretion [33]. The increase in urinary phosphate excre-
tion when the subjects were eating the low calcium diet is
consistent with this action of l,25-(OH)2-D. Alternatively, the
lower dietary calcium content, by limiting the precipitation of
brushite or apatite within the intestine, may have made more
dietary phosphate available for absorption. Another possibility
is that the additional urinary phosphate might derive from the
skeleton if 1,25-(OH)2-D stimulated bone resorption.
Previous studies suggest that l,25-(OH)2-D3 can also stimu-
late intestinal magnesium absorption in patients with chronic
renal failure who have low serum 1,25-(OH)2-D levels [341. But
in other studies, we were unable to detect a significant relation-
ship between intestinal magnesium absorption and serum 1,25-
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(OH)2-D concentrations [121. The present studies support the
view that l,25-(OH)2-D does not significantly enhance intestinal
magnesium absorption because serum magnesium concentra-
tions fell and urinary magnesium excretion did not change as
serum 1,25-(OH)2-D levels rose (Table 2). The reductions in
serum magnesium levels were not significantly correlated to
reductions in serum PTH concentrations (normal calcium diet, r
= 0.50, P> 0.2; low calcium diet, r= 0.46; P > 0.2). Thus, we
were unable to document either inhibition of the known effect of
PTH to enhance renal tubular magnesium reabsorption [35] or
the previously described parallel relationships between changes
in serum magnesium and changes in serum PTH during dietary
calcium deprivation and loading [36] and during dietary phos-
phate deprivation [15].
Patients with hypercalciuria and nephrolithiasis may exhibit
slightly increased daily urinary oxalate excretion [37] and
increased urinary oxalate excretion after the oral administration
of either sodium oxalate [38] or '4C-oxalate [39]. Urinary
oxalate excretion has been shown to increase in normal subjects
eating low calcium diets [40]. Serum l,25-(OH)2-D levels were
not measured in these studies but were likely high in the
hypercalciuric patients and above normal in the healthy sub-
jects deprived of dietary calcium. Our data confirm these
observations because fasting urinary oxalate rose as serum
l,25-(OH)2-D concentrations increased. Speculatively, when
the diet contains oxalate and serum 1 ,25-(OH)2-D levels are
elevated thus promoting maximal intestinal calcium absorption,
binding of oxalate within the gut lumen would be reduced. This
would result in a rise in the concentration of free oxalate in the
intestine, enhancing oxalate absorption, and increasing urinary
oxalate excretion. Increased urinary oxalate concentrations, as
well as hypercalciuria, are important risk factors in the patho-
genesis of calcium oxalate stone formation [41].
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